Načítá se...
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot placebo-controlled trial
OBJECTIVE: Obsessive-compulsive disorder (OCD) affects approximately 2.5% of the population and is associated with significant morbidity. Many patients receive little benefit from the best available treatments, and even those who do respond often suffer from significant residual symptoms. Convergent...
Uloženo v:
| Vydáno v: | J Clin Psychiatry |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4560666/ https://ncbi.nlm.nih.gov/pubmed/26214725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4088/JCP.14m09123 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|